[144] Corcept Therapeutics Inc. SEC Filing

Rhea-AI Filing Summary

Corcept Therapeutics Inc. (CORT) filed a Form 144 notifying a proposed Rule 144 sale of 40,000 common shares through Stifel Nicolaus & Company Inc., with an aggregate market value of $2,788,800 and an approximate sale date of 09/02/2025. The filing reports the shares were acquired on 07/06/2022 by stock option exercise and paid for in cash. The filing also discloses recent sales by the same named seller, Joseph Belanoff: 40,000 shares on 06/02/2025 for $3,314,310, 615 shares on 07/17/2025 for $45,318, and 40,000 shares on 08/04/2025 for $2,742,006. The issuer’s total shares outstanding are listed as 105,370,000. The notice includes the seller’s representation that he has no undisclosed material adverse information.

Positive

• Transaction transparency: The filing provides acquisition date, nature of acquisition, broker, and payment details.
• Recent sales disclosed: Three recent sales with gross proceeds are listed, giving clear context for recent insider activity.

Negative

• Limited issuer contact details: The excerpt does not show complete filer CIK or submission contact information.
• No 10b5-1 plan date: The filing does not indicate a trading plan adoption date, so plan-based affirmative defense is not documented here.

Insights

Securities Analyst

TL;DR: Executive stock sales disclosed; amounts are measurable but routine under Rule 144.

The filing documents a proposed sale of 40,000 shares valued at $2.79 million and confirms acquisition via stock option exercise on 07/06/2022. The seller, identified in prior sale rows as Joseph Belanoff, completed multiple sales in recent months totaling significant proceeds. For investors, these are transparent, reportable transactions under Rule 144 rather than corporate operational developments. The entry lists 105.37 million shares outstanding, providing context for the relative size of the sale (approximately 0.038% of outstanding shares). No earnings, guidance, or corporate actions are disclosed here.

Compliance/Risk Analyst

TL;DR: Filing meets Rule 144 disclosure elements; no compliance exceptions or undisclosed material information shown.

The Form 144 includes broker details, acquisition method (stock option exercise), payment method (cash), and recent sales by the same named seller. The seller’s attestation regarding lack of undisclosed material adverse information is present. There are no statements of plan adoption under Rule 10b5-1 shown. From a compliance perspective, the document supplies the required transaction details but does not include the filer CIK or full submission contact details in the presented excerpt.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Stifel Nicolaus & Company Inc. 501 N Broadway St. Louis MO 63102	40000	2788800.00	105370000	09/02/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/06/2022	Stock Option Exercise	Corcept Therapeutics Inc.			40000	07/06/2022	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Joseph Belanoff 101 Redwood Shores Parkway Redwood City CA 94065	Common	06/02/2025	40000	3314310.00
Joseph Belanoff 101 Redwood Shores Parkway Redwood City CA 94065	Common	07/17/2025	615	45318.00
Joseph Belanoff 101 Redwood Shores Parkway Redwood City CA 94065	Common	08/04/2025	40000	2742006.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Corcept Therapeutics (CORT) report in this Form 144?

The Form 144 notifies a proposed sale of 40,000 common shares valued at $2,788,800 with an approximate sale date of 09/02/2025.

Who acquired the shares being sold and how were they acquired?

The 40,000 shares were acquired on 07/06/2022 by stock option exercise from Corcept Therapeutics and paid for in cash.

What recent sales by the same seller are disclosed?

The filing shows Joseph Belanoff sold 40,000 shares on 06/02/2025 for $3,314,310, 615 shares on 07/17/2025 for $45,318, and 40,000 shares on 08/04/2025 for $2,742,006.

How large is the proposed sale relative to outstanding shares?

The issuer reports 105,370,000 shares outstanding; the proposed sale of 40,000 shares is about 0.038% of that total.

Which broker is handling the proposed sale?

The broker listed is Stifel Nicolaus & Company Inc., 501 N Broadway St. Louis MO 63102.